JP2023504186A5 - - Google Patents

Info

Publication number
JP2023504186A5
JP2023504186A5 JP2022533064A JP2022533064A JP2023504186A5 JP 2023504186 A5 JP2023504186 A5 JP 2023504186A5 JP 2022533064 A JP2022533064 A JP 2022533064A JP 2022533064 A JP2022533064 A JP 2022533064A JP 2023504186 A5 JP2023504186 A5 JP 2023504186A5
Authority
JP
Japan
Prior art keywords
peptide
construct
construct according
hhhk
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504186A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063676 external-priority patent/WO2021113851A2/en
Publication of JP2023504186A publication Critical patent/JP2023504186A/ja
Publication of JP2023504186A5 publication Critical patent/JP2023504186A5/ja
Pending legal-status Critical Current

Links

JP2022533064A 2019-12-06 2020-12-07 標的化された核酸送達のためのペプチドドッキング賦形剤 Pending JP2023504186A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945042P 2019-12-06 2019-12-06
US62/945,042 2019-12-06
PCT/US2020/063676 WO2021113851A2 (en) 2019-12-06 2020-12-07 Peptide docking vehicle for targeted nucleic acid delivery

Publications (2)

Publication Number Publication Date
JP2023504186A JP2023504186A (ja) 2023-02-01
JP2023504186A5 true JP2023504186A5 (cg-RX-API-DMAC7.html) 2024-01-10

Family

ID=76222046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533064A Pending JP2023504186A (ja) 2019-12-06 2020-12-07 標的化された核酸送達のためのペプチドドッキング賦形剤

Country Status (11)

Country Link
US (1) US12054714B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069261A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023504186A (cg-RX-API-DMAC7.html)
KR (1) KR20220115579A (cg-RX-API-DMAC7.html)
CN (1) CN114885604B (cg-RX-API-DMAC7.html)
AU (1) AU2020398192A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022010883A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160576A1 (cg-RX-API-DMAC7.html)
IL (1) IL293589A (cg-RX-API-DMAC7.html)
WO (1) WO2021113851A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207211B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物
CN117836006A (zh) * 2021-08-04 2024-04-05 和博医药有限公司 用于递送治疗活性剂的配体缀合物
US12673115B2 (en) * 2021-08-11 2026-07-07 Arizona Board Of Regents On Behalf Of Arizona State University Nucleic acid-peptide-nucleic acid conjugate molecules and methods of making the same
WO2023049807A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Improved methods for preparing nanoparticle compositions containing histidine-lysine copolymers
WO2026032280A1 (zh) * 2024-08-06 2026-02-12 北京茵诺医药科技有限公司 寡核苷酸缀合物、含有该寡核苷酸缀合物的组合物及制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812016A4 (en) * 2004-11-17 2010-07-14 Univ Maryland HIGH-BRANCHED HK-PEPTIDES AS EFFECTIVE CARRIER FROM SIRNA
US8575123B2 (en) * 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP3373979A1 (en) * 2015-11-12 2018-09-19 Pfizer Inc Tissue-specific genome engineering using crispr-cas9
KR102775461B1 (ko) * 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
AU2017296195A1 (en) * 2016-07-11 2019-01-24 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
EP3526328A4 (en) * 2016-10-17 2020-05-27 Apellis Pharmaceuticals, Inc. COMBINATION THERAPY FOR C3 INHIBITION
JP7512207B2 (ja) * 2018-05-24 2024-07-08 サーナオミクス インコーポレイテッド 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法

Similar Documents

Publication Publication Date Title
JP2023011614A5 (cg-RX-API-DMAC7.html)
EP2611927B1 (en) Novel single chemical entities and methods for delivery of oligonucleotides
JP2021533199A5 (cg-RX-API-DMAC7.html)
JP2021507686A5 (cg-RX-API-DMAC7.html)
JP5583667B2 (ja) 長時間作用型dnaデンドリマーおよびその方法
JP2023537798A5 (cg-RX-API-DMAC7.html)
JP2025106480A5 (cg-RX-API-DMAC7.html)
JP7291418B2 (ja) Pcsk9を標的としたアンチセンス核酸
CN102686243B (zh) 用于抗癌剂递送的聚合物系统
CN1211923A (zh) 增强生物分子的细胞摄取的配体
EP2976109B1 (en) Cellular delivery of dna intercalating agents
JP2008512097A (ja) アプタマー医薬品化学
TWI726844B (zh) 胜肽載體上之多重寡核苷酸部分
CN104244987A (zh) 新型寡核苷酸缀合物及其应用
CN114885604B (zh) 用于靶向递送核酸的肽对接载体
JP2016513089A (ja) 細胞への遺伝子送達のための機能性dnaデンドリマー
JP2023172954A5 (cg-RX-API-DMAC7.html)
AU2004232848A2 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2024533427A5 (cg-RX-API-DMAC7.html)
JP2023524812A5 (cg-RX-API-DMAC7.html)
CN115244064A (zh) 治疗性分子的靶向递送
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
JP2024512783A (ja) 核酸の自己組織化媒介adc薬の構築方法および適用
TW202218687A (zh) 骨骼肌遞送載體及其使用方法
Sarkar et al. Recent developments in the delivery of peptide nucleic acids (PNAs)